ClinicalTrials.gg
CompletedNCT03312595Updated Sep 16, 2025Results posted

Clinical Outcomes After Treatment With RestrataTM Wound Matrix in Diabetic Foot Ulcers (DFU)

An interventional study of Restrata TM Wound Matrix in Diabetic Foot Ulcer, sponsored by Acera Surgical, Inc.. Completed at 5 sites in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-16.

Sponsored by Acera Surgical, Inc. (part of Solventum) · Not applicable, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Diabetic Foot by Solventum — none open to participants now, none under way, none of them phase 3. Diabetic Foot · Solventum.

Started
2017
the only one that year
No phase
8 of 12
none open now
Registered
10th of 12
by date

Among the 12 studies in Diabetic Foot by Solventum, this one is the only one that started in 2017, is one of 8 with no phase, and was the 10th registered.

Diabetic Foot

1,079 studies on the registry are indexed under Diabetic Foot; 222 are open to participants now.

Browse Diabetic Foot studies →

Open to participants now

None of the 12 studies in Diabetic Foot by Solventum is open now. The open studies under Diabetic Foot, anywhere →

Who these studies take

Of the 137 Diabetic Foot studies recruiting now, 96 (70%) set no upper age limit and 12 (9%) stop at 75 or younger; 5 take children under 18; 10 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Diabetic Foot by Solventum as a file.
02

Study summary

The primary objective of this study is to determine the outcomes of patients who receive a certain type of skin substitute called RestrataTM Wound Matrix (Restrata™). Results of this study may be used to make decisions on whether to conduct additional studies on this particular wound matrix product. RestrataTM has been cleared by the Food and Drug Administration for use in certain types of ulcer treatments, including the type that will be part of this study (diabetic foot ulcers).

Read the detailed description

Control Group: None (Utilize historical / published data on outcomes using standard of care)

Test Group: Treatment of DFUs with RestrataTM Wound Matrix

Study Type: Interventional

Study Design: Allocation: Non-randomized Endpoint Classification: Efficacy Intervention Model: Direct assignment Masking: Single Blind (Subject) Primary Purpose: Treatment

03

Conditions studied

  • Diabetic Foot Ulcer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female age 18 or older
  • Patient's ulcer must be diabetic in origin, located at least in part on the plantar surface and larger than 1cm2 after the run-in period. Debridement will be done prior to randomization. Subject's for participating in this study, must be obtained prior to proceeding with sharp debridement
  • Patients with Type 1 or Type 2 diabetes (criteria for the diagnosis of diabetes mellitus per ADA).
  • Ulcer must be present for a minimum of four weeks before enrollment/randomization, with documented failure of prior treatment to heal the wound. A two-week run in period will precede enrollment/randomization in the trial to document the indolent nature of the patients selected
  • Patient does not exhibit clinical signs / symptoms of infection upon gross observation (at least 3 of the following: pain, redness, purulence, exudate, temperature) or have been diagnosed with an active infection at time of screening
  • Patient is willing to provide informed consent and is willing to participate in all procedures and follow up evaluations necessary to complete the study
  • Patient has adequate control of diabetes, as demonstrated by one of the following within 30 days of screening:

    • \< 12%
    • Serum Creatinine \< 3.0mg/dl
  • Patient has adequate circulation to the affected extremity, as demonstrated by one of the following within the past 60 days of the first screening visit:

    • Dorsum transcutaneous oxygen test (TcPO2) with results

      ≥30mmHg, OR

    • ABIs with results of ≥0.7 and ≤1.5, OR
    • Doppler arterial waveforms, which are triphasic or biphasic at the ankle of affected leg

Exclusion criteria

Exclusion Criteria:

  • Patients presenting with an ulcer probing to bone (UT Grade IIIA-D)
  • Patients whose index diabetic foot ulcers are greater than 25cm2
  • Patient has an additional wound within 3cm of the study wound
  • Patients not in reasonable metabolic control
  • Patients with a known history of poor compliance with medical treatments
  • Patients who have been previously enrolled into this study, or are presently participating in a clinical trial with DFU indications
  • Patients with known or suspected local skin to the index diabetic ulcer
  • Patients diagnosed with connective tissues diseases
  • Patients that have received a graft material on the study ulcer within the previous 30 days
  • Patients who are pregnant or breast feeding
  • Patients who are taking medications that are considered immune system modulator
  • Study wound has closed > 30% over the two-week run-in period
  • Patients with a known allergy to resorbable suture materials
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Other
    Restrata TM Wound Matrix

    Prospective, single armed, non-randomized study with direct assignment

    Device: Restrata TM Wound Matrix

Interventions

  • DeviceRestrata TM Wound Matrix

    The RestrataTM Wound Matrix is a sterile, single use device intended for use in local management of wounds

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Wound Closed

    from baseline at week 0 to 14 weeks

    Time frame: Up to 14 weeks

Secondary outcomes

  1. Change in Wound Area From Baseline

    Wound area measurements will be made via tracing acetate every week for 14 weeks.

    Time frame: Baseline and weekly for up to 14 weeks

  2. Time to Wound Closure

    The number of weeks until complete closure is first identified will be determined for each patient who has been deemed completely closed within the 14 week treatment period.

    Time frame: Baseline up to 14 weeks

07

Results

Posted Apr 26, 2021

Participant flow

Participant flow — Overall Study
MilestoneRestrata Wound Matrix
Started30
Completed24
Not completed6

Outcome measures

PrimaryPercentage of Participants With Wound Closed

from baseline at week 0 to 14 weeks

Time frame:
Up to 14 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Wound Closed
percentage of participantsRestrata Wound Matrix
Percentage of Participants With Wound Closed75
SecondaryChange in Wound Area From Baseline

Wound area measurements will be made via tracing acetate every week for 14 weeks.

Time frame:
Baseline and weekly for up to 14 weeks
Reported as:
Mean · % wound area change
Change in Wound Area From Baseline
% wound area changeRestrata Wound Matrix
Change in Wound Area From Baseline96 ± 10
SecondaryTime to Wound Closure

The number of weeks until complete closure is first identified will be determined for each patient who has been deemed completely closed within the 14 week treatment period.

Time frame:
Baseline up to 14 weeks
Reported as:
Mean · weeks
Time to Wound Closure
weeksRestrata Wound Matrix
Time to Wound Closure6.4 ± 2.5

Adverse events

Collected over 3.5 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Restrata Wound Matrix0/24 (0%)0/24 (0%)12/24 (50%)
Most frequent other events
Most frequent other events
EventRestrata Wound Matrix
InfectionGeneral disorders3/24
TraumaGeneral disorders2/24
OsteomyelitisGeneral disorders2/24
BlisterGeneral disorders2/24
FeverGeneral disorders1/24
Peripheral vascular diseaseGeneral disorders1/24
New ulcerGeneral disorders1/24

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Restrata Wound Matrix
<=18 years0
Between 18 and 65 years19
>=65 years1
Sex: Female, Male
Sex: Female, Male(Participants)Restrata Wound Matrix
Female2
Male18
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Restrata Wound Matrix
08

Study locations

5 sites
  • Associated Foot & Ankle Specialists
    Phoenix, Arizona 85015, United States
  • Arizona Reginal Medical Research
    Tucson, Arizona 85710, United States
  • SAVAHCS
    Tucson, Arizona 85723, United States
  • Advanced Foot Care And Clinical Research Center
    Fresno, California 93722, United States
  • Richard C. Galperin, DPM
    Dallas, Texas 75208, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Jul 2018, 10 months.

Results were first posted in Apr 2021, 2 years 9 months after primary completion.

Of 104 industry-sponsored interventional studies with no phase under Diabetic Foot, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 40. This study's 10 months is below that.

Counting every sponsor, half of 344 studies reached it within 22 months; a quarter within 9 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2017
First posted
Oct 18, 2017
StartActual
Sep 14, 2017
Primary completionActual
Jul 15, 2018
CompletionActual
Jul 30, 2018
Results first posted
Apr 26, 2021
Last update
Sep 16, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 16, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03312595
Responsible party
Sponsor
First posted
Oct 18, 2017
Start date
Sep 14, 2017
Primary completion
Jul 15, 2018
Completion
Jul 30, 2018
Results posted
Apr 26, 2021
Last update
Sep 16, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion